New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care
New data show strong performance of.
Full year 2023 revenue growth of 25% driven by clinical volume growth of 39%
Expects full year 2024 revenue to be in the range of $655 to $670 million
.
Guardant Health, Inc. , a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
Fourth Quarter 2023 Financial Highlights
Revenue of $155.1 million for the fourth quarter of.